Symptomatic Control of Neuroendocrine Tumours with Everolimus

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Control of carcinoid syndrome with everolimus

(2011) J. Capdevila et al.   ANNALS OF ONCOLOGY

Current knowledge on diagnosis and staging of neuroendocrine tumors

(2011) Kjell Öberg et al.   CANCER AND METASTASIS REVIEWS

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Health-Related Quality of Life in Patients With Neuroendocrine Tumors With Quality of Life in the General US Population

(2011) Jennifer L. Beaumont et al.   PANCREAS

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population

(2009) Trude Haugland et al.   QUALITY OF LIFE RESEARCH

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY